167 related articles for article (PubMed ID: 9152970)
21. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
Luikart SD; Herndon JE; Hollis DR; MacDonald M; Maurer LH; Crawford J; Clamon GH; Wright J; Perry MC; Ozer H; Green MR
Am J Clin Oncol; 1997 Feb; 20(1):24-30. PubMed ID: 9020283
[TBL] [Abstract][Full Text] [Related]
22. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
McCowage GB; White L; Carpenter P; Lockwood L; Toogood I; Tiedemann K; Shaw PJ
Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
[TBL] [Abstract][Full Text] [Related]
24. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
25. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
[TBL] [Abstract][Full Text] [Related]
26. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
Yeung AW; Pang YK; Tsang YC; Wong SW
Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
[TBL] [Abstract][Full Text] [Related]
27. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
[TBL] [Abstract][Full Text] [Related]
28. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
[TBL] [Abstract][Full Text] [Related]
29. [Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
Shi YK; Sun Y; Su M
Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):356-9. PubMed ID: 7895587
[TBL] [Abstract][Full Text] [Related]
30. A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
Weiss GR; Shaffer DW; DeMoor C; Rinaldi DA; Rodriguez GI; Eckardt JR; Stephens C; Von Hoff DD
Anticancer Drugs; 1996 Jun; 7(4):402-9. PubMed ID: 8826608
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
32. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
33. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; Cordonnier C; de Revel T; Simon M; Nicolini F; Stoppa AM; Janvier M; Bordessoule D; Rousselot P; Ffrench M; Marie JP; Archimbaud E
Leukemia; 1999 Aug; 13(8):1214-20. PubMed ID: 10450749
[TBL] [Abstract][Full Text] [Related]
34. Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy.
Jost LM; Pichert G; Stahel RA
Ann Oncol; 1990 Nov; 1(6):439-42. PubMed ID: 1707298
[TBL] [Abstract][Full Text] [Related]
35. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
[TBL] [Abstract][Full Text] [Related]
36. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
37. Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study.
Ardizzoni A; Sertoli MR; Corcione A; Pennucci MC; Baldini E; Intra E; Ferrarini M; Rosso R; Mazzanti P; Pistoia V
Eur J Cancer; 1990; 26(9):937-41. PubMed ID: 2177614
[TBL] [Abstract][Full Text] [Related]
38. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF.
Alvarado Ibarra ML; Borbolla Escoboza JR; López-Hernández MA; González-Avante CM; FloresChapa JD; Trueba Christy E; Anaya Cuellar I
Rev Invest Clin; 1999; 51(2):77-80. PubMed ID: 10410585
[TBL] [Abstract][Full Text] [Related]
40. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
